On January 7, 2021 TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, reported that it has been invited to attend the 39th annual JP Morgan Healthcare Conference, scheduled to take place January 10-14, 2021 (Press release, Taiwan Liposome Company, JAN 7, 2021, View Source [SID1234573669]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

JP Morgan Healthcare Conference has been and is the largest and most information healthcare investment symposium in the industry, with attendance of over 8,000 participants each year. This year, the conference will be conducted entirely virtually over the internet instead of physically taking place at the Westin St. Francis Hotel in San Francisco as per tradition, in an effort to impede the spread of COVID-19.

TLC will be attending the conference for the seventh year in a row at the invitation-only event. Members of TLC’s management team will provide updates on the status of the Company’s innovative product candidates, including TLC599 and TLC590, which are non-opioids with the potential to provide extended relief of osteoarthritis pain and postsurgical pain, respectively.